LianBio’s TP-03 Begins Phase III Trial for Demodectic Blepharitis in China
Shanghai-based biopharmaceutical company LianBio (OTCMKTS: LIANY) has announced the first patient dosing in a Phase...
Ascletis Files IND Application for COVID-19 Oral Inhibitor ASC11 with FDA
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that the Investigational New Drug (IND) application...
RemeGen’s Telitacicept Shows Positive Results in Phase II Myasthenia Gravis Study
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has released data from a Phase II...
Immunochina Pharmaceuticals Raises Funds for Gene Therapy Development
Beijing-based gene therapy specialist Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in...
BGI Genomics Receives NMPA Approval for Chromosome Aneuploidy Detection Kit
China-based genomics firm BGI Genomics Co., Ltd (SHE: 300676), the Shenzhen-listed subsidiary of BGI Group,...
NMPA Suspends GSK’s Avodart Amid Inspection Findings
The National Medical Products Administration (NMPA) has decided to suspend the import, sales, and use...
Antengene’s ATG-017 Gets FDA Approval for Phase I Clinical Study
Antengene Corporation has announced receiving approval from the US Food and Drug Administration (FDA) to...
China Grand’s STC3141 Reaches Primary Endpoint in ARDS Phase Ib Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib clinical study...
Allogene Overland Biopharm Completes State-of-the-Art AlloCAR T Facility in Shanghai
Allogene Overland Biopharm, a joint venture between Overland Pharmaceuticals and Allogene Therapeutics, Inc. (NASDAQ: ALLO),...
Shandong Buchang Partners with REMD Bio for Bispecific Antibody Development
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced a co-development and licensing agreement...
Eucure Biopharma Partners with ISU ABXIS to Develop Tri-Specific Antibodies Using YH003
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...
Zhejiang Medicine’s ARX788 Advances to Phase II Study for HER2-Positive Cholangiocarcinoma
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has received approval from the National Medical Products...
Simcere’s SIM0235 Begins US Phase I Trial for Anti-Tumor Therapy
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the enrollment of the first patient in...
China’s National Plan to Combat Microbial Drug Resistance Released
The National Health Commission (NHC), Ministry of Education, Ministry of Science and Technology, and 10...
Sanofi’s Q3 Sales Rise 9% on Dupixent and Flu Vaccine
French pharmaceutical major Sanofi (NASDAQ: SNY) released its Q3 2022 financial report, recording EUR 12.482...
Novartis’ Cosentyx Gains Approval for New Doses in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval for two new specifications...
XtalPi Partners with Janssen to Accelerate Drug Discovery
China-based XtalPi, Inc. has announced a research collaboration with Janssen Pharmaceutica NV, one of the...
NMPA Approves Kyowa Hakko Kirin’s Mogamulizumab for Sezary Syndrome and Mycosis Fungoides
Kyowa Hakko Kirin China Pharmaceutical Co., Ltd’s mogamulizumab, a first-in-class chemokine receptor type 4 (CCR4)...
NMPA Grants Second Approval to Henlius’ Serplulimab for Lung Cancer
The National Medical Products Administration (NMPA) has granted a second marketing approval to HaiSiZhuang (serplulimab),...
Innovent’s CLDN18.2 ADC IBI343 Begins Phase I Trial in Australia
Innovent Biologics Inc. (HKG: 1801) has announced the first subject dosing in a Phase I...